Dyax has extended partnership with Bayer Pharma for access to Dyax's antibody phage display technology for the development and potential commercialization of therapeutic antibody candidates identified using the phage display library.
The extension of the partnership was based on successful antibody discovery work during a research evaluation period.
Dyax spokesperson Gustav Christensen said the company is providing Bayer with our proven technology for their antibody discovery efforts.
"With the first program from our evaluation period already moving ahead to the next research milestone, we look forward to continuing support of Bayer’s efforts to maintain and enhance its world-class biologics pipeline," Christensen added.
The phage display technology has powered therapeutic and diagnostic candidate discovery across a range of therapeutic areas, according to Dyax.